Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Rob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple Artemisinin Combination Therapies to the All-Party Parliamentary Group on Malaria & NTDs on March 19th in Westminster at the Houses of Parliament.

Rob van der Pluijm in Westminster © Credit: Andrea Stewart

Did you know? In the UK, members of parliament (MPs) from different political parties form All-Party Parliamentary Groups to discuss themes of particular importance to the UK government and its populace.

The APPG on malaria and NTDs gathered March 19 in Westminster; Jeremy Lefroy MP welcomed Rob van der Pluijm on behalf of MORU, the Tracking Resistance to Artemesinin Collaboration II and the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project.

Rob presented encouraging findings from TRAC II and launch plans for DeTACT in Africa and Asia. The UK Department for International Development’s (DfID) Senior Global Health Advisor attended alongside colleagues from the Wellcome Trust, LSHTM, Imperial College and other malaria advocacy groups.

Pertinent questions included whether DeTACT was an innovative attempt at ‘global health preparedness’ for eventual drug resistance in Africa; whether the WHO and national health programmes in endemic countries were likely to recommend triple dose treatments soon enough to prevent or slow the impact of drug resistance; and how well Mefloquine was tolerated when part of the Triple ACT combination.

Read a summary of the Westminster event.

Photo: APPG on Malaria & NTDs Chair Jeremy Lefroy MP (right) and Catherine West MP (second right), together with Rob van der Pluijm (centre) and other research presenters from LSHTM and Nottingham University. Text and photo credit: Andrea Stewart.

Similar stories

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Geneva Health Forum panel on the elimination of NTDs and the new WHO Roadmap

Conferences & meetings OCGHR

The WHO 2030 NTD Roadmap has just been launched, and a recent Geneva Health Forum panel took that as its starting point to discuss the possibility of eliminating neglected tropical diseases (NTDs). Professor Philippe Guérin, IDDO’s Director, joined co-panellists Dr Amy Fall, the Global Health Medical for Africa Region Lead at Sanofi, Dr Mwele Malecela, Director of the Department of Control of Neglected Tropical Diseases at the WHO, and Dr Nathalie Strub-Wourgaft, Medical Director at Drugs for Neglected Diseases initiative (DNDi) back in November 2020.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.